Emily Tomasulo, DO, FACP
Medical Oncology, Hematology
Accepting new patients
Sees patients age 18 and up
Penn Hematology/Oncology Pennsylvania Hospital
View 1 additional location
Make an appointmentCall 800-789-7366
Penn Medicine Provider

About me

  • Assistant Professor of Clinical Medicine (Hematology-Oncology)

Education and training

  • Medical School: Philadelphia College of Osteopathic Medicine
  • Residency: Pennsylvania Hospital
  • Fellowship: National Institutes of Health

What my patients think about me

Average Rating

398 reviews

Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.

November 2025
very professional
November 2025
she put me at ease
November 2025
great communicator
November 2025
she was excellent

Insurance accepted

My Locations

Penn Medicine hospital privileges

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
  • Pennsylvania Hospital: Has privileges to treat patients in the hospital.
Dr. Tomasulo is a Penn Medicine physician.

Qualifications and experience

Treatments and Conditions

My research

Emily Tomasulo, Andy Itsara, Mark Haigney, Douglas R. Rosing, Inhye E. Ahn, Cody Peer, Beth A. Kozel, Teresa Luperchio, Grace Ge, William D. Figg, Adrian Wiestner, and Clare Sun Sudden Death and Asymptomatic Arrhythmia in CLL Patients Treated with Ibrutinib , Heart Rhythm: 2025

Christopher Pleyer, Emily Tomasulo, et. al Activity and Safety of Venetoclax without Anti-CD20 Lead-in Therapy in Treatment Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia , Blood Supplement, American Society of Hematology Annual Meeting, San Diego, CA.: 2024

Emily B. Tomasulo, Dylan Therwhanger, Emeline R. Chong, Mitchell E. Hughes, Michael Fradley, and Stephen J. Schuster Resolution of ibrutinib-associated hypertension with transition to alternate covalent BTKi , Blood Supplement, American Society of Hematology Annual Meeting, San Diego, CA.: 2024

Emily Tomasulo, Shira Paul, Rui Mu, Xin Tian, Jonathan Chen, Christopher Pleyer, Adrian Wiestner, Clare Sun Interruption of BTK inhibitor improves response to SARS-CoV-2 booster vaccination in patients with CLL , Leukemia & Lymphoma, 64(14): 2023,2306-2315.

Itsara A, Sun C, Bryer E, et al. Long-Term Outcomes in Chronic Lymphocytic Leukemia Treated with Ibrutinib: 10-Year Follow-up of a Phase 2 Study , Blood Supplement, American Society of Hematology, Washington, DC: 2023

Emily Tomasulo Chronic Lymphocytic Leukemia Chapter , Bethesda Handbook of Hematology: 2023

Bryer E, Itsara A, Ahn I et al. Ibrutinib-associated sudden death in patients with CLL , Blood, American Society of Hematology, Orlando, FL., 140(Supplement 1): 2022

Bryer EJ, Destefano C, Kazandjian D. Current and prospective antibody-based therapies in multiple myeloma , Semin Oncol, 49(1): 2022,41-47

Bryer EJ, Stein E, Goldberg S. Multivessel Coronary Artery Disease , Mayo Clinic Proceedings: Innovations, Quality, and Outcomes.: 2020

Bryer E, Dew A, Hill E, et al. A phase II pilot study of avelumab in combination with hypofractionated radiotherapy in patients with relapsed refractory multiple myeloma , Blood, 136(Supplement 1): 2020